World Health Organization (WHO) , COVID19 Case Series of Post Covid 19 Rhino Orbito Cerebral Mucormycosis in Egypt

Case Series of Post Covid 19 Rhino Orbito Cerebral Mucormycosis in Egypt

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06267326

Enrollment

Registered

2024-02-20

Start date

2021-05-23

Completion date

2023-08-21

Last updated

2024-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19, Mucormycosis; Rhinocerebral (Etiology)

Brief summary

Objectives: identify and recognize clinical Characteristics, Pathophysiology, and management of a group of patients with rhino Rhino-Orbito-Cerebral Mucormycosis infection associated with Covid 19 viral infection

Interventions

PROCEDUREdebridment

resection of dead bone

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

SINGLE (Caregiver)

Eligibility

Sex/Gender

ALL

Age

22 Years to 77 Years

Healthy volunteers

Yes

Inclusion criteria

* all patients with mucormycosis post covid 19

Exclusion criteria

* The patient not suffered from covid 19

Design outcomes

Primary

Measure	Time frame	Description
35 patients suffering from mucormycosis infection post covid 19	2 years	Ratio Scale. Visual Analog Score for pain Ratio Scale. Ratio Scale. ratio scale
25 patients were cured with comorbidity and 10 pateints died	2 years	ordinal scale Visual Analog Score for pain
pain	two years	Visual Analog Score for pain

Secondary

Measure	Time frame	Description
Visual Analog Score for pain	2years	pain

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026